Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation

NARecruitingINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

January 17, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

July 31, 2025

Conditions
Opioid Use Disorder
Interventions
OTHER

Treatment as usual (TAU)

TAU entails medication to support patients' recovery (i.e., the partial opioid agonist, buprenorophine + naloxone/ Suboxone gel films), in-person case management and behavioral health intervention (i.e., in-person group and individual counseling), and referrals to other health care and behavioral health services.

OTHER

CHaRRM-CN

The CHaRRM-CN intervention includes changes and additions to TAU to make MAT more culturally aligned (i.e., offering regular community-based, cultural programming; offering culturally aligned healing groups in the MAT program, such as Talking Circles and beading group) as well as lower barrier and incentivized (i.e., offering medication and behavioral health appointments via in-person, videoconference or telephone; offering harm-reduction groups in addition to abstinence-based groups; providing mailed and in-person pick-up options for buprenorphine prescriptions; conducting weekly chart reviews to ensure prescriptions and basic needs are continuously met; bimonthly, automated text outreach; contingency management supporting attendance at in-person or telehealth appointments).

Trial Locations (2)

74464

RECRUITING

Cherokee Nation Health Services, Tahlequah

98195

ACTIVE_NOT_RECRUITING

University of Washington School of Medicine, Seattle

All Listed Sponsors
collaborator

University of Washington

OTHER

collaborator

Cherokee Nation Health Services

UNKNOWN

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Washington State University

OTHER